To The Moon

Kezar Life Sciences, Inc. (Nasdaq:KZR)103% HIGHER; reported positive topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with active lupus nephritis (LN).

Spero Therapeutics, Inc. (Nasdaq:SPRO)8% LOWER; received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) seeking approval for tebipenem HBr oral tablets for treatment of adult patients with complicated urinary tract infection (cUTI), including pyelonephritis. The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022.

Spirit (NYSE:SAVE)5% HIGHER;JetBlue (NASDAQ:JBLU) today announced that it is modifying its proposal toacquireSpirit (NYSE:SAVE) based on discussions with Spirit shareholders.

Nike (NYSE:NKE)2.4% LOWER; reported Q4 EPS of $0.90, $0.09 better than the analyst estimate of $0.81. Revenue for the quarter came in at $12.2 billion versus the consensus estimate of $12.07 billion. The Company announced its Board of Directors has authorized a new four-year, $18 billion program to repurchase shares of NIKE's Class B Common Stock

Morgan Stanley(NYSE:MS)3% HIGHER; announced that it will increase its quarterly common stock dividend to $0.775 per share from the current $0.70 per share, beginning with the common dividend expected to be declared by the Firm’s Board of Directors in the third quarter of 2022. In addition, the Firm’s Board of Directors authorized a new multi-year common equity share repurchase program of up to $20 billion, without a set expiration date, beginning in the third quarter of 2022

The Goldman Sachs Group, Inc. (NYSE:GS)2% HIGHER;announced plans to increase its common stock dividend from $2.00 to $2.50 per share following the stress test.